Reshaping trade for vaccine equity: gaps in policy discourse

# Authors:

Toby Pepperrell<sup>1\*</sup>, Meri Koivusalo<sup>2</sup>, Liz Grant<sup>1</sup>, Alison McCallum<sup>3</sup>

<sup>1</sup>Global Health Academy, University of Edinburgh, UK

<sup>2</sup> Faculty of Social Sciences, Tampere University, Finland

<sup>3</sup> Usher Institute, University of Edinburgh, UK

\*Corresponding author

E-mail: v1tpeppe@ed.ac.uk

**Author Contribution statement:** AKM and TP conceived and designed the study with critical input from MK. TP and AKM prepared, analysed and undertook the initial interpretation of the data. LG and MK provided critical advice. TP and AKM wrote the first draft; ALL edited and revised drafts; MK and AKM are guarantors. All authors have read and approved the final version of this paper.

#### Abstract

The recent Pandemic Agreement negotiations illustrate significant gaps in action required to respond effectively to the lessons of the COVID-19 pandemic and make progress towards public health goals, including SDGs. The pandemic revealed vaccine equity as a unifying health need, and international trade as a Commercial Determinant of Health. We explored where policy action could reshape trade relationships, identifying recommendations for vaccine equity in stakeholder literature pertaining to Free Trade Agreements (FTAs).

We searched online libraries for stakeholder documents that focused on the interface between FTAs, vaccination, and vaccine equity published between 01/01/2010-31/03/2022. Using the rights, regulation and redistribution (3R) framework, recommendations were categorised as Technical Mechanisms, Collaborative and Adaptive Mechanisms, or Determinants of Vaccine Equity. These were then located on a novel systems map to elucidate gaps and actions.

No cohesive strategies for change were identified. Technical proposals were reactive, repetitive, and lacked enforcement mechanisms or incentives. There were significant gaps in the articulation of alternative Collaborative Mechanisms to democratise FTA policymaking processes. The underlying Determinants of Vaccine Equity and lack of policy coherence were not addressed. These findings are limited by underrepresentation of low- and middle-income country authorship, demonstrating deep institutional and methodological barriers to change, and reflecting imbalances in international policymaking processes.

Overall, our research shows how the current trade paradigm has produced and sustained vaccine inequity, leading a synthesis of action proposals. Transformation of FTA policy is essential and urgent, particularly since new technologies will be crucial for the global response to emerging, neglected, and non-communicable diseases that are vaccine-preventable or -modifiable. Multilateral organisations must, therefore, prioritise the right to health above FTAs serving corporate over community interests, including through TRIPS waiver on Essential Technologies.

## Introduction

Despite globally agreed mechanisms to prioritise global public health over short-term commercial interests and partisan actions by individual governments, vaccine delivery in the COVID-19 pandemic has been inequitable [1]. The Doha agreement and World Trade Organisation (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities have proven inadequate in scope and deployment. On May 5, 2023, as the World Health Organisation (WHO) declared the acute pandemic over, low-income countries (LICs) had delivered 5.65-times fewer vaccine doses per adult than high-income countries (HICs) (0.39 versus 2.26; GitHub and World Bank data) [2-4]. It is vital to understand why global access to vaccines has not been achieved.

The role of the Commercial Determinants of Health (CDH) in pandemic preparedness must be examined, including their contribution to vaccine inequity [5,6]. International trade and profit-related movements of goods, people and services played a key role in the emergence and development of the COVID-19 pandemic, including pathways to delivering essential technologies [7]. Vaccines have not traditionally been seen as commercially traded products, but part of international cooperation and national public health provision by governments. However, policies and practises arising from Free Trade Agreements (FTAs) have affected the manufacture and distribution of vaccines, delaying global vaccination. There is now awareness that FTAs are having a similar impact on vaccine equity as with new medicines.

Vaccines emerge from basic and translational research predominantly funded by the public sector. The expectation that COVID-19 vaccines would be viewed as global public goods (GPGs) was reflected in the resolutions in the 2020 World Health Assembly and UN General Assembly [8,9]. Instead of acting in global solidarity, however, HIC blocs concentrated vaccine supply, disrupted efforts to pool and distribute vaccines in line with need, and resisted efforts to increase and diversify manufacturing capacity in favour of delayed and inadequate charitable distribution [10]. Vulnerable people and healthcare professionals in low- and middle-income countries (LMICs) remained under-vaccinated, while countries above the charitable income limit found their vaccine supplies delayed, less reliable, and often more expensive than HICs [10].

FTAs promote early market capture of policies related to GPGs at all stages from conception to distribution (Fig 2) with limited attention to the purpose of immunisation as fundamental to the right to health. For example,

most FTAs strengthen Intellectual Property (IP) law, protection of trade secrets and commercial interests beyond the WTO minimum (TRIPS-plus agreements) [11]. There is, however, scope for vaccines and vaccination-related services to be considered essential health services and global public goods with long-term benefits [12].

We must ask: What can be learned from existing measures and prior global outbreaks? Do trade goals conflict with vaccine equity? What policy incoherencies enable capture by non-health interests? What are the existing narratives for change and who is framing them?

We examined gaps in policy, policy recommendations, and action, with a focus on the role of the WTO and FTAs in the pathways to vaccine equity using the publicly available work of international policymaking bodies and Non-Governmental Organisations (NGOs) with key responsibilities in this area.

### Methods

We undertook a stakeholder review of the grey literature, complementing an earlier scoping of the peerreviewed academic literature [13]. We defined stakeholders as organisations with a formal role as policy actors, for example the WTO, SDG custodians, NGOs (international public health bodies, charities, donors, and professional/trade governing bodies with roles in vaccine supply) (Appendix 1).

We searched online libraries for documents that focused on the interface between FTAs, vaccination, and vaccine equity between June 1 and August 31, 2022, enhanced by reference searches and alerts to identify material such as WTO papers becoming publicly available.

We conducted initial screening and then formally searched for English language documents published between 01/01/2010-03/06/2022, to cover the period from 5 years before the adoption of the SDGs, capturing their effects on trade policy related to vaccines, up until the date of our latest search, which covered the entire period of initial COVID-19 vaccine distribution. SDG 3, particularly Target 3.0.b.01 on universal access to vaccines, provided a formal, global commitment to vaccine equity [14]. It was used as a reference against which we could measure adoption and implementation of policy and practices likely to function as facilitators and barriers to vaccine equity, meeting the UN expectation that trade would be harnessed to meet SDG requirements [15]. The documents retrieved formed our dataset (Appendix 2). Appendix 3 includes search terms and PRISMA diagram [16]. We repeated the search on 04/05/2024 to assess whether additional recommendations with transformational potential emerged in response to continuing vaccine inequity in the 2 years after the end of the acute phase of the pandemic.

We followed the documentary analysis method outlined by Dalglish et al: readying, extracting, analysing, and distilling findings from each document and the relationships between them [17]. Two authors (TP and AKM) skimmed titles and abstracts to determine primary focus, before reviewing in detail to identify policy proposals, actions, and outcomes. We discussed and agreed the findings, fitting them to an analytic framework.

Our analytic framework builds on earlier work examining current and potential future approaches to developing sustainable public health and vaccine pathways. We applied and adapted the submission from the Globalisation

Knowledge Network to the WHO Commission on the Social Determinants of Health on the Rights, Regulation, Redistribution (3R) framework (Fig 1) [18]. We looked specifically at factors that would affect enforcement of the right to health, impact multilateral regulation for equity in vaccine development and distribution. These factors were mapped onto the analytic framework: Determinants of Vaccine Equity, Technical Mechanisms, and Collaboration and Adaptation around the global free trade environment. Subcategories from the 3R framework were expanded as themes emerged in analysis.

[Fig 1: Analytical framework adapted from the Rights, Regulation and Redistribution Framework]

The overarching categories can be considered at three positions along Meadows' leverage points to intervene in a system [19]. Technical Mechanisms are proximal and visible, addressing specific gaps without effecting deep or sustainable change; Collaborative approaches, shared goals, professional and organisational responsibilities, can enable greater cohesion; Determinants are underlying causes from which pervasive political and commercial health effects emerge.

We discussed the findings first as broad themes under each category and then examined the subcategories, focusing on advancing vaccine equity at specific points in the causal process (Fig 2). This allowed us to interrogate which recommendations could be transformative and identify gaps.

[Fig 2: Systems map showing points of policy capture from vaccine research and design through to marketisation and distribution.]

## Results

We screened 10,000 documents by abstract and title, 115 papers and reports met our eligibility criteria and underwent full text review (Appendix 2). Sixty-nine were subsequently excluded as they contained no action points (n=25), provided only basic information (n=18), provided no health (n=9), or trade policy (n=8) commentary, full text was inaccessible (n=6), or they were not international (n=3) (Appendix 3). Of the 46 documents included, only 12 came from stakeholders in the Global South (Appendix 1). Stakeholder references from the repeated search were not included in the dataset, as they did not pertain to the acute phase of the pandemic or reveal any novel recommendations, but search results are available on request.

We identified 267 recommendations likely to influence vaccine equity. Those that could enable significant vaccine progress towards SDG 3 were considered potentially transformational (Table 1). Technical Mechanisms constituted 152/267 (56.9%) proposals, of which 12/152 (7.9%) were considered potentially transformative, 48/267 (18.0%) focused on Collaborative and Adaptive Mechanisms, of which 8/48 (16.7%) were transformative, while 67/267 (25.1%) addressed Determinants of Vaccine Equity, with 9/67 (13.4%) transformative (Table 1). Our updated search identified no new transformational recommendations, though additional examples of Technical and Collaborative mechanisms were identified for points a.ii, c.ii, d.ii, g.i, i, o.iii in Table 1 [20-27].

Table 1: recommendations in the available policy literature around (a.) Technical and (b.) Collaborative & Adaptive mechanisms to improve vaccine equity, and (c.) the Determinants of vaccine equity. \*Links to Dataset Appendix 2, not bibliography.

Category a. Subcategory i) Themes in findings Technical mechanisms		Recommendations		
		Number (/267)	Potentially transformational (/29)	
		152	12	
a.	Patents       i)       FTA consultation with WIPO, WTO and WHO on public health measures         ii)       TRIPS modifications and TRIPS-plus flexibilities         iii)       Voluntary and compulsory licensing mechanisms         iv)       Emergency measures	39	a.ii.iii.iv.1 Patent waiver during time of pandemic for vaccine technologies and components, vaccines, and vaccine-related products, including know-how and bilateral education programmes (2*, 7*, 8*, 35*, 43*, 61*, 74*, 88*)	
b.	<ul> <li>Financial regulation and governance <ul> <li>i) Regulation of FTAs</li> <li>ii) Health technology markets and foreign investment</li> <li>iii) TRIPS flexibilities and compulsory licensing, article 31</li> <li>iv) Direct trade interventions</li> <li>v) Health system strengthening methodology</li> </ul> </li> </ul>	36	<ul> <li>b.i.1 Primacy of public health in FTA negotiations (2*, 38*, 42*)</li> <li>b.i.2 Open investigation of effects of trade openness on deforestation and zoonotic risk to be moderated by land rights and financial guidelines (89*)</li> <li>b.i.1 International investment rules transparency, multilateral framework alongside SDGs (72*)</li> <li>b.iii.1 Real discourse on technocratic and political barriers to employing TRIPS flexibilities (38*, 42*, 46*, 55*, 58*)</li> <li>b.v.1 Debt crisis solutions to be brokered through United Nations in recognition of public health effects (66*)</li> </ul>	
c.	Products       i)       International harmonisation and clarity         ii)       Vaccine inputs and global supply chain         iii)       Wider production capacity         iv)       Charitable interventions         v)       Emergency measures	19	c.i.ii.iii.iv.v.1 Experimental policies to address barriers to supply diversification (20*, 27*, 93*)	
d.	Procurement i) Self-determination: procurement policy that reflects national priorities ii) Multilaterally mediated pooled procurement process for all LMICs iii) Competition and equity iv) Transparency	16	d.ii.1 Deepen and expand pooled procurement mechanisms (7*, 8*, 20*, 43*, 69*, 88*, 105*) d.i.ii.iii.iv.1 New approaches to procurement by prequalification based on potential harms of lack of rapid and equitable vaccine access (8*)	
e.	Health technology assessment i) International harmonisation and clarity ii) Transferability iii) Clinical trial data iv) Cost-benefit approach to prequalification	15	e.i.iii.iii.iv.1 International collaborative approach to health technology assessment, and agreed criteria for rapid assessment and approval in any nation (5*, 6*, 8*, 35*, 44*, 74*)	
f.	Border control i) Import-export restrictions and tariffs ii) Bottlenecks iii) Paperless trade iv) Long-term agreement and definitions	14		
g.	Technology transfer       i)       Access included in governance of privatisation of public research (Bayh-Dole equivalent public tasks for private corporations)         ii)       Pooled access initiatives require engagement at R&D phase	7	g.i.1 Public health criteria strengthening: Bayh Dole equivalents (legislation to ease commercialisation of high-priority products resulting from public research) to have 'march in' rights if companies not enabling products to be made or distributed at appropriate scale to meet public health needs (104*) g.i.2 These policies must include equitable access provision at the point of public-to-private technology transfer (2*)	

h.	Secrecy and restrictions i) Intellectual Property law	6	
	Collaborative and adaptive mechanisms	48	8
i.	Information sharing and transparency i) Data and know-how within and between healthcare systems ii) Cost transparency for negotiation capacity	21	i.i.ii.1 Interoperable data sharing systems (8*) i.i.ii.2 Designing transparency into all practices from research through development, including funding and conflict of interest (6*, 35*)
j.	International declarations       i)       Balance of corporate compared to community rights and obligations         ii)       Revising outdated or dysfunctional agreements         iii)       Novel agreements	17	j.i.ii.1 Broad vaccine delivery partnership boosting microplanning through advocacy and political engagement within UN – integrated ground level teams associated with regional and global partners (111*) j.iii.1 Minimum requirement of Medical Innovation Prize Fund – strategic global health benefit at generic price (104*)
k.	One Health i) Universal Healthcare ii) Vaccine programmes iii) Environmental	8	k.iii.1 Uniform minimum environmental standards to be agreed for FTAs, with civil society involvement (116*)
1.	Traditional knowledge i) Registry and recording ii) Patentability and protection	2	<ul> <li>1.i.ii.1 Enforceable rights for custodians of traditional knowledge to protect knowledge streams and ensure benefit sharing from resultant innovations (48*)</li> <li>1.i.1 Essential R&amp;D into fostering R&amp;D potential and knowledge-based infrastructure led by discriminated populations in LMICs (104*)</li> </ul>
	Determinants of vaccine equity	67	9
m.	Gaps in regulation         i)       Empirical policy debate and legislation         ii)       Borders         iii)       Pricing         iv)       Safety, pharmacovigilance, and ethics         v)       Corporate and professional conduct related to vaccination	28	m.i.1 Address imbalance in corporate vs planetary interests by moving from best endeavour e.g. labour, environment, agriculture, public health requirements into hard law commitments similar to e.g. finance, capital investment, IP rights (116*) m.i.iv.v.1 Design pharmaceutical education curricula and care plans to meet local needs from practice level assessment and not just minimum international guidelines (43*)
n.	Inequities in research capacity i) Regulatory ii) Innovation iii) Validity iv) Access to medicines v) Transparency	21	n.i.ii.iii.iv.v.1 Law to support local R&D and enshrine regulation of major corporations undertaking R&D and production in diverse settings (104*) n.i.ii.iii.iv.v.2 National self-definition of R&D priorities before externally imposed intergovernmental definition (43*)
0.	Inequity in health need and access i) Rights-based financial support ii) Fiscal justice iii) Addressing harms and gaps in right to health	11	o.i.ii.1 Nuanced financial framework responding specifically and appropriately to socially determined health needs in a rights-based manner, rather than national income (46*, 53*) o.ii.iii.1 Open discourse and action on impacts of debt repayments, especially interest above initial loan, on health systems and pandemic response (66*) o.ii.ii.1 Structural provision for women's rights organisations to mitigate the gendered impacts of the pandemic and vaccine inequity (66*)
р.	Gaps in healthcare coverage i) Funding wastage ii) Healthcare worker movement and rights	7	<ul> <li>p.i.1 Diversification and sustainable funding of prevention, treatment, and care pathways through agreements around global public goods or generic provision, avoiding excessive spending on specific proprietary technologies that crowd out other aspects of service provision (104*)</li> <li>p.ii.1 Special mutual recognition for migrant healthcare workers, and free movement (88*, 103*)</li> </ul>

#### **Thematic Analysis**

We drew out the processes involved in vaccine development, production, distribution, and service delivery, and identified where FTAs and trade-related policies and procedures had the potential to facilitate or constrain efforts to progress vaccine equity.

#### **Technical Mechanisms**

Development and application of technical mechanisms that limit or facilitate access to vaccines dominated the policy discourse. Technical recommendations focused on addressing vaccine inequity post-policy capture (Fig 2). Patents, supply chain and borders issues dominated (Table 1, a.-d., f.), tending to provide workarounds to mitigate short term harm rather than transformation.

Almost two-thirds of regional FTAs include TRIPS-plus agreements [28]; one vaccine can entail multiple patents and trade secrets covering essential technologies and processes [29]. Without access provisions at a public-private technology transfer stage, new FTAs and TRIPS-plus agreements afford market exclusivity to the few companies that own patents, proprietary technology, and trade secrets for periods that extend beyond the acute phase of an outbreak or pandemic. Few stakeholders acknowledged the importance of early intervention to support public development, prevent or limit exclusive licensing (Fig 2, a.-c.), and assure adequate governance to prevent market domination and excessive profit-taking (Table 1, g., h., i., n.iv.v). Without effective interventions, supply is capped. In addition, few countries produce vaccines, so most governments have limited scope to use domestic legislation to address emerging inequities, ensure affordability, or investment in infrastructure development.

Documentary analysis repeatedly identified Article 31 on TRIPS flexibilities [30]. Compulsory licensing is designed to combat TRIPS-related inequity of access to medicines, but complexity, potential costs, and lengthy timescales have limited its use (b.iii.1) [31,32]. Concern about the risk of trade and non-trade sanctions has limited repurposing of existing facilities and reverse engineering of vaccines (Table 1, b.iii.1, c.i.ii.iii.iv.v.1) [33]. Significant effort has been expended on complex negotiations and workarounds, while the WTO has recognised that TRIPS flexibilities were designed to address national rather than global emergencies [34]. To effect responsive vaccination to curtail a polio outbreak in Israel, the manufacturer waived the patent voluntarily, enabling local production [35]. The original compulsory licensing framework relied on exceptional

conditions and, when designed, did not anticipate the range of behaviours of companies or vaccine-producing trading blocs that now distort the relationship between supply and need [32]. Few stakeholders addressed the relatively weak measures available to address failures to protect public health. Legal measures to formalise research ethics and public protections in law were key themes despite receiving little public attention.

#### **Collaborative and Adaptive Mechanisms**

We identified calls for open communication and information sharing with interested parties (Table 1, i.). Among the best-established examples are those for globally sharing intelligence, tissue, data, and expertise to support horizon-scanning and syndromic surveillance for emerging threats to health for vaccine preventable and modifiable diseases [36]. These efforts sit alongside advocacy for clinical trial transparency, action on price negotiations, epidemiological mapping and supporting infrastructure [37,38]. However, Collaborative Mechanisms should provide alternative means of resolving trade related issues related to vaccine equity. Significant gaps and inconsistencies impede this possibility [39]. In addition, while some grassroots and NGO efforts addressed supply chain issues, the role for other than market-based actors or activities, including governments, was minimal.

Collaborative and adaptive approaches should provide enabling mechanisms for public health FTA exemptions as a minimum, as attempted by the Medicines Patent Pool (MPP) [40]. However, such efforts remain context and topic specific. Without a systems approach, positive examples remain largely invisible to wider FTA decision-making. Equity must be upheld as a collaborative process and outcome, but we found public health measures reduced to specific interventions, reflecting hard-won, case-by-case global health diplomacy rather than progress towards system redesign. We found no proposals for community or grassroots representation in decision-making processes from the bodies responsible for multilateral governance.

## **Determinants of Vaccine Equity**

There was no clear pathway to deliver vaccine equity in line with the requirement for universal access to vaccines. The Doha Declaration on the TRIPS agreement and Public Health and subsequent amendments allow for measures to address public health problems, including through vaccination [32,41]. However, we found limited evidence of attention to the structural, systemic, and institutional barriers to vaccine equity associated with FTAs including the trade-related issues that complicated the response to Ebola [42,43]. After limited

11

progress towards a more comprehensive pandemic waiver in WTO [44], equity and access questions during pandemics are now considered within Pandemic Agreement negotiations (potentially Committee E) and revision of International Health Regulations (IHR) [45].

#### Analysis of Specific Recommendations

Technical recommendations frequently referenced procompetitive corporate governance (Table 1, a.-b.). Suggested amendments to patent challenging processes such as patent thickets and evergreening complicate an already resource intensive pathway for LMICs to access vaccines within WTO rules [37]. Corporate rights also dominated policy discourse. Narrowly drawn recommendations may illustrate a deliberately incremental approach favoured by some authors but there was little evidence of a strategic plan for vaccine equity in the stakeholder literature [46]. Just 6/152 recommendations (3.9%) addressed secrecy and restrictions (h.), and 7/152 (4.6%) technology transfer (g.), both crucial to vaccine equity.

Twelve Technical proposals were potentially transformational (Table 1). One, patent waiver (a.ii.iii.iv.1), directly addressed patents, trade secrets and non-patent related IP (a., h.). Propositions included a multilateral investment framework compatible with the SDGs (b.ii.2), breaking down barriers to employing TRIPS flexibilities (b.iii.1), and equitable vaccine research and production processes with 'march in' rights where products are not being made or distributed at scale to meet public health needs (g.i.1-2).

Collaborative recommendations focused largely on pre-existing declarations (17/48, 35.4%) (j.) such as implementation of TRIPS amendments or mechanisms designed to increase transparency (21/48, 45.8%) (i.) [30]. These often fall back on best endeavours rather than enforceable requirements or agreements formalising collective commitments, intelligence, and action. Potentially transformational recommendations included more comprehensive commitments to transparency and knowledge sharing (i.i.ii.1-2), alternative vaccine delivery partnerships (j.i.ii.1) and unlocking LMICs' R&D potential. (l.i.1).

Recommendations considering the social, political, and commercial Determinants of Vaccine Equity as a subset of health equity – other than increasing average national income – were infrequent. Discourse on the determinants of health revolved around gaps in (financial) regulation and increasing the potential of LMICs to

undertake innovative commercial health technology research (49/67, 73.1%) (m.-n.) rather than attention to rights, redistribution, or sustainability (o-p.).

Gaps in healthcare provision, access to care (11/67, 16.4%) (o.) and underlying causes of health and healthcare inequities that manifest as barriers to vaccine equity were overlooked (7/67, 10.4%) (p.). In the Determinants category, potentially transformational recommendations included calls to strengthen legislation around planetary health versus corporate interests (m.i.1), tailored financial support to address the social determinants of health at community (o.i.ii.1) and macro levels, including addressing the impacts of debt repayments (o.ii.iii.1).

## **Inter-related Nature of Recommendations**

The relationships between individual recommendations were clear but largely unacknowledged. Technical Mechanisms often depended on Determinants of vaccine equity, for example releasing resources for health system strengthening by revoking or minimising the impact of debt repayments (b.v.1, o.ii.iii.1), but without a clear Collaborative bridge for mobilisation, for example as seen with the recommendation for national self-determination of research and healthcare goals in LMICs (e.ii.iii.iv.1, l.i.1, n.i.ii.iii.iv.v.1-2).

## Discussion

There was insufficient recognition of FTA impact on vaccine equity in the international stakeholder literature. Attempts to apply incremental fixes such as 31bis in practice, or even case by case approaches such as compulsory licensing mechanisms, were not linked to new forms of collaboration or solution-building. Siloed technical solutions overwhelmed efforts to address the building blocks of vaccine equity such as reforming undemocratic decision-making, power imbalances, enabling technology transfer and addressing barriers including patent thickets and trade secrets.

Vaccine equity could have been designed into the global pandemic response, but efforts were diverted by a best endeavour framing of public health needs lacking the enforceability of corporate rights. The European Union, the UK, and the US were able to veto the COVID-19 technologies TRIPS waiver despite support from around 100 nations and calls for international cohesion from WHO, WTO and WIPO leadership [47]. As new WTO regulations require consensus, countries with stronger negotiating positions can block transformational proposals, limiting progress towards vaccine equity. Trade-offs and compromises across different areas of negotiation can also undermine improvements. WTO and WIPO are thus unlikely to be able to support transformative measures to enhance vaccine equity but will be bound to expanded and strengthened global agreements.

## Addressing Gaps in the Current Approach to Addressing Vaccine Equity

Technical Mechanisms are vital tools that can enable introduction of specific interventions that address barriers or enable vaccine equity. However, they link to no coherent strategy in the policy discourse. Discussions on cocreated models of financial support (o.i.ii.1) were overshadowed by those imposed by HICs and multilateral organisations, particularly GDP and World Bank national income category as proxies for resource availability. MSF Access reports illustrate that LMICs are subject to cliff edges in funding from international development organisations like Gavi when national income or GDP reaches an externally imposed threshold [48]. There has been little recognition that modelling and pricing processes do not take need, purchasing power parity or affordability into account. Rather than assuring the right to health, the global COVID-19 vaccine programme has been directed by growth-oriented FTA economics that simplifies complex geopolitics. There were no

proposals for more inclusive shaping of international trade beyond the existing WTO regulation of FTAs. Instead, energy had to be directed towards resolving preventable issues like vaccine dumping.

Costa Rica's proposal for a global technology and IP pool in March 2020 and Eswatini, India, Kenya, and South Africa's proposal for a TRIPS waiver were important interventions that were rebutted [49,8]. Instead, underdeveloped Collaborative Mechanisms and limited multilateral governance undermined the ACT-A and COVAX collaborations and the additional emergency measures proposed. This failure is reflected in the IHR and Pandemic Agreement negotiations as LMICs advocacy for global equity has received significant pushback [50,52]. An enforceable global IP pool or TRIPS+ waiver including action regarding, for example, trade secrets or measures to limit profiteering, would have facilitated greater vaccine equity and informed wider corporate regulation.

Unlike the current proposals, access goals should be enshrined in law, supporting progress towards SDG 3 commitments, including universal access to vaccines. Existing mechanisms requiring corporations to fulfil public tasks before allowing the exclusive licensing of essential medicines and technologies that limits their distributive potential in health emergencies, could be built on. This would extend the disaster prevention and major incident response requirements placed on certain industries to pandemics [52]. IP regulations must ensure that public health measures can be enacted rapidly, dismantling patents or trade secrets as barriers. To build on the success of the pre-prepared protocols and mechanisms for rapid resourcing and implementation of SARS-CoV-2 vaccine trials there must be pre-defined conditions and methods for waiving patents and trade secrets on pandemic products, failing removal from TRIPS coverage [53]. While these issues, including benefit-sharing, are included in the Pandemic Agreement, the scope indicates limited progress [50].

Vaccine equity requires a focus on collaboration over competition. Corporate commitments to transparency may be welcome first steps but will not deliver the improvements in the determinants of vaccine equity or lower vaccine need; they have previously been used to argue that deeper change to IP and trade secrets is unnecessary [54]. This implies that the transformative potential of cooperative action and non-for-profit collaboration has not been considered. Without greater connection between populations, developments like the MPP cannot function as desired. The lack of an overarching strategic approach means that exclusion and inequity are baked into

current FTA governance. For equity to be integral to pandemic preparedness, decision-making must centre independent regional, NGO, and grassroots civil society, currently excluded from closed-door negotiations.

Our stakeholder review found that power imbalances, postcolonial trade justice and human rights obligations, were under-recognised [55]. LMIC voices, particularly in-country NGOs, and advocacy bodies, were barely present; we identified only 12 policy documents from the Global South. Without a critical lens on how policymaking processes contribute to the determinants of health, opportunities for vaccine equity were missed throughout the pandemic. For example, available mRNA vaccines had exacting cold chain requirements. Community-based LMIC-led innovation could reduce barriers to local production, energy- and resource-dependent delivery, and hesitancy [42,43].

Action to address the flaws and limitations of current multilateral governance mechanisms is required, particularly in relation to the roles of the WTO and the WHO. Table 2 gives our synthesis of priorities for action. Trade is a tool, not an outcome, and public health must be consistently central to FTA negotiations, with enforceable definitions of compliance with the right to health as a corporate obligation rather than a taskspecific, incentivised, discretionary mechanism.

Aims	Objectives to address policy incoherence	Immediate steps
Overarching Develop a strategic plan for vaccine equity Democratise multilateral decision- making for FTA governance Strengthen equity of FTA negotiations Ensure equitable capacity for policy analysis	<ul> <li>Strategic plan         <ul> <li>Redefine trade as a tool for addressing planetary health and social determinants of health</li> <li>Address the need for repeated use of short-term technical and complex to implement fixes for systemic problems</li> <li>Develop enabling mechanisms to ensure trade strategies can be a tool to achieve SDG 3</li> <li>Consider wider application of lessons from analysis of trade related barriers to vaccine equity</li> </ul> </li> <li>Multilateral decision-making         <ul> <li>Involve all UN recognised states in global trade governance mechanisms with clear roles and responsibilities</li> <li>Create a system of general agreement and majority voting rather than requirement for unanimous support before consensus declared</li> <li>Enable nations to act without fear of sanctions that limit policy space for health</li> <li>Centre human rights-based approaches and discriminated voices in designing more equitable policy and decision-making processes</li> <li>Develop legal requirement to fulfil extra-territorial responsibilities in the present, recognising debt justice and the need to incorporate historical reparations for colonial activity, and subsequent inequitable and welfare-punitive material and immaterial flows of goods and services</li> </ul> </li> <li>FTA negotiations         <ul> <li>Enable prioritisation of planetary health equity</li> <li>Evidence sub-national community representation in FTA negotiations</li> <li>Optimise benefits and mitigate adverse impact of FTAs on LMICs essential infrastructure and resources avoiding financial cliff-edges</li> <li>Create fully supported transparent and globally equitable trade negotiation and mediation systems with LMIC leadership</li> </ul></li></ul>	Strategic plan         • Strengthen WHO capacities to engage with and provide technical assistance on trade- and health equity -related questions         • Convene joint working programme led by WHO, bringing World Health Assembly participants and observers into conversation with WTO and WIPO to measure policy gaps against priorities for vaccine equity held by all nations         • Require joint working for next round of pandemic treaty negotiations         • Bring technical mitigations against vaccine inequity and incremental technical improvements into one workstream         • Map steps required to ensure trade strategies can be a tool to achieve SDG 3         • Translate analytical framework for application to other public health problems         Multilateral decision-making         • Formally agree upon and prioritise the determinants of vaccine equity in decision-making on international trade policy         • Strengthen role of human rights in decision-making and interpretation of trade and investment agreements         • Require comprehensive health impact assessment of new and revised FTAs and associated policies         • Provide an independent voice to advocate for non-WTO member states and people of disputed territories         FTA negotiations         • Esclude essential health services like immunisation from FTAs         • Require equity impact assessment in advance of FTA development         • Establish a programme of engagement and joint work with discriminated communities so that equity is designed into future negotiations and revisions         • Ensure that
	<ul> <li>Policy analysis</li> <li>Reduce the resource intensive nature of policy review and analysis, making it possible for LMIC countries and institutions to undertake independently without relying on discretionary access to Global North funding</li> </ul>	<ul> <li>Policy analysis         <ul> <li>Enable transparency and access to literature and public data globally</li> <li>Include vaccine availability, access, and equity in assessment of how trade agreements relate to policy space for health policies and health systems financing</li> <li>Support automation of processes of finding, identifying and prioritising literature for review to maximise the use of scarce expert resources, including through natural language processing</li> <li>Require search engines and repositories approved for use in literature review in policymaking, research, and teaching to include access to published research and policy documents from the Global South, particularly in-country NGOs and civil society organisations working with stigmatised and minoritised populations</li> </ul> </li> </ul>

# Table 2: Priorities for action, building on recommendations from the stakeholder review (Appendix 2) and addressing gaps in the pathway to vaccine equity (Fig 2)

Pre-commercialisation (Fig 2, a-b) Address global research inequity	<ul> <li>Definition of research goals by and with LMIC stakeholders</li> <li>Routine sharing of knowledge and know-how to enable globally equitable design and scale up of vaccine programmes</li> </ul>	<ul> <li>Require corporate bodies to fulfil public tasks as a condition of public funding of research, including funding in kind e.g. use of health facilities or human volunteers</li> <li>Enhance clinical trial transparency and assessment of cost-effectiveness of novel treatments against existing medicines, including new vaccines</li> <li>Reduce the scale and duration of intervention generated inequity by ensuring that novel health interventions can be implemented in LMIC populations as a priority</li> <li>Ensure full sharing of knowledge and know-how regarding use of vaccine components including any technological innovations</li> <li>Maximise distributive potential during health emergencies as an obligation for companies and other parties commercialising research</li> </ul>
Commercialisation (Fig 2, c-d) Establish mechanisms to strengthen the global IP pool	<ul> <li>Make TRIPS+ waivers easily enforceable in emergency scenarios</li> <li>Strengthen global IP pool to allow essential technologies and platforms to be safely produced in and for LMICs</li> </ul>	<ul> <li>Create working group to prioritise transition to more inclusive global IP pool, built around existing endeavours of WHO with WIPO support</li> <li>Reduce and geographically limit exclusive licensing practices to a level compatible with ensuring compliance with SDG 3</li> <li>Expand list of essential technologies which cannot be licensed exclusively</li> <li>Enshrine legal requirement for equitable access at research translation rather than procurement stage</li> </ul>
Procurement       o       Democratise finance policymaking and debate mechanisms         Fig 2, e-g)       o       Strengthened investment accountability to support sustainable health interventions based on SDGs         mplement more equitable models of clobal financing and procurement       o       Co-create adaptable, inequity-focused financial support models not based on Gross National Income cut-offs		<ul> <li>Collaboration on vaccines procurement to ensure production quality and sustainability</li> <li>Account for need, purchasing power parity, and affordability in financial support without imposed conditions or compound interest</li> <li>Develop and monitor a programme of knowledge exchange on financing models</li> <li>Require full transparency of cost of goods, medicines and technologies including purchasing power parity</li> </ul>

# Strengths and Limitations of This Study

We examined publicly available material that documented and analysed existing and proposed policy positions and mechanisms. We included international policy and advocacy organisations advising or negotiating trade-related agreements, or proposing solutions to address public health in FTAs. By reviewing complementary sources on a timeline designed to analyse progress towards the SDGs, particularly universal access to vaccines, we achieved saturation of key themes [56]. However, we could not identify all potential stakeholders due to gaps in discoverability, global representation in on-line databases, language restrictions, and a Westernised lens on free trade in multilateral organisations. We recognise that, as Pandemic Agreement negotiations have developed, additional evidence is emerging. Our findings, therefore, must be considered as the minimum required for action and we are conscious that novel approaches, alternative narratives and priorities for action from those populations most affected by the adverse impact of trade-related factors on vaccine equity may have been overlooked or misinterpreted.

#### **Towards a New Framework**

We found that action to address vaccine inequity could be evaluated using the 3R framework. By taking a systems approach, the relationships between specific Technical, Collaborative, and Determinant policy interventions could be mapped onto Meadows' points of leverage to intervene in a system, highlighting transformative potential [19]. Achieving vaccine equity requires action on two fronts: a strategic plan bringing together the implementation of incremental and transformational improvements and a broader framework that centres the Determinants of Vaccine Equity.

The systems map of factors affecting vaccine equity shows the interlinked nature of the action required. Technical recommendations, for example, depend on new forms of collaboration by addressing areas where policies affecting the right to health are contested. Without shifts to the wider context in which technocratic measures evolve, access initiatives remain reactive, politically unfeasible, at risk of capture or overwhelm by corporate interests as with COVAX [57]. For example, compulsory licensing and/or waiving trade secrets (Technical) to enhance production of and access to vaccines are necessary due to a lack of equity in research and technology transfer (Determinants), as seen with SARS CoV-2 vaccines [1], but even pooling mechanisms (Collaborative) are not employed, reflecting fear of sanction or non-preference in FTAs .

While development, application and evaluation of technical fixes can mitigate harm, these measures alone will not achieve vaccine equity. For example, where the policy literature focused on tariff reductions to lubricate the production chain (Table 1, f.), FTAs could, instead, exclude essential health services such as immunisation, with vaccines as essential medicines excluded or technically exempted from the articles on procurement, investment and commercialisation of services that contribute to inequities in access. A framework for addressing vaccine inequity must prioritise the determinants of health, while developing new policy spaces by strengthening collaborative mechanisms to make changes stick, and then applying technical mechanisms to enable

implementation. Pandemic Agreement negotiations could still provide the basic wiring with the Conference of Parties and Committee E as fora for such measures.

## Addressing Determinants of Vaccine Equity

The vaccine requirements of populations with high exposure and risk of harm during the COVID-19 pandemic could have been predicted if the determinants of vaccine equity had been considered and the technical and collaborative mechanisms aligned. Instead, countries with high-risk environments and significant levels of multimorbidity, Global South nations that hosted clinical trials, like South Africa [58], experienced avoidable harm from delayed supply and excess cost of vaccines [59]. Few recommendations supported policy action to manage countries' evolving health needs and inequities. Precipitous GDP-related removal of support when reaching externally imposed thresholds was also hardly covered. Global actors responsible for vaccine programmes must acknowledge FTA-related factors and protect against increasing health inequities, rather than presuming increasing national income as result of trade will enable universal access to healthcare.

# **Building Blocks**

The WTO and WHO now have Global South leadership and more progressive ambition than before the pandemic. This must translate into action. Global negotiations to develop a pandemic treaty endeavour to address equity, trade- and IP-related issues, but have made limited progress and risk removing effective recommendations. WTO decision-making must adapt to address planetary health challenges; longer-term constitutional change and progress in addressing wider CDH is glacial. The roles of the WTO and multilateral organisations in FTAs have been widely criticised by LMICs, especially the difficult and inequitable dispute mechanisms [60,61]. It should be possible for Member States to support strengthening the role of WHO in relation to the wider determinants of health, including planetary health, and reposition the WTO with more effective global oversight. Multilateral bodies must have the capacity to create the conditions that enable countries to pass laws to hold corporations accountable for fulfilling their public responsibilities, promoting more equitable decision-making. Collective efforts should enable countries to translate currently unenforceable best endeavours agreements regarding health and its determinants into laws to protect public health, with the precautionary principle at the heart of pandemic preparedness. As a first step, this means WTO engaging with all populations regardless of UN state classification, rather than WTO members only, with space for an independent voice to advocate for peoples of disputed territories. Recent progress on multilateral governance in relation to tax provides a model worthy of further exploration as similar agreements could set out agreed minimum standards for countries to address gaps in current laws [62,63]. Meanwhile, to increase FTA transparency and accessibility, formal observer status should be granted to representatives of national public health bodies and independent civil society organisations. This should be

20

complemented by joint working to measure gaps in policy against priorities held by all nations undertaken in collaboration with WHO, through its collaborating centres.

Vaccine equity is a planetary health challenge for which FTAs could be an enabling mechanism rather than a barrier. A systems approach to multilateral governance centring Determinants would enable just and nuanced support for health needs, increase visibility of levers that hinder progress in multiple dimensions of health justice, facilitating a clearer path to action.

## Conclusion

The complex web of policy decisions that constitute FTAs has shaped vaccine inequity and the course of the COVID-19 pandemic. There can be no international tolerance for this scale of inequity. Here we have illuminated trade as a CDH, a link previously difficult to track but made clear by analysing barriers to vaccine equity. We have shown why institutional change is often refractory, making visible the distortion of public benefits by corporate policy capture, and the prevention of transformation from sole focus on technical measures. Known injustices and harms have deepened as a result. Our framework is transferable to other public health problems, for example, environmental change and pandemic propensity.

A framework for the transformation of FTAs is urgent, with interventions developed, tested and their impact evaluated. To facilitate action and analysis, a new multilateralism is needed. Our review identified steps towards a new framework, but our methodology is limited by potential publication bias, the lack of Global South and independent community representation. Future work must reduce inequity in discoverability of scholarship and research with an easily accessed and updated policy bank for LMIC sources. Sustainable vaccine equity requires that we transform the relationship between trade and the determinants of health. This requires an overhaul of the processes by which policy is made and governed, changing how we move towards collective planetary outcomes.

Acknowledgements: We are grateful for the support of Dr Siddharth Basetti, NHS Scotland, for fruitful discussions and support with organising and checking data.

## References

- 1 Mantilla KK, Barona CC. COVID-19 Vaccines as Global Public Goods: Between Life and Profit: *South Centre*. 2022.
- 2 Mathieu E, Ritchie H, Ortiz-Ospina E et al. A global database of COVID-19 vaccinations. *Nature Human Behaviour* 2021; **5**(7): 947-53.
- 3 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2021. Available from: <u>https://R-project.org/</u>
- 4 Wickam H, Averick M, Bryan J, Chang W, McGowan LD, Yutani H et al. Welcome to the tidyverse. *Journal of Open Source Software* 2019; **4**(43): 1686.
- 5 Friel S, Collin J, Daube M et al. Commercial determinants of health: future directions. *The Lancet* 2023; **401**(10383): 1229-40.
- 6 Freeman T, Baum F, Musolino C et al. Illustrating the impact of commercial determinants of health on the global COVID-19 pandemic: Thematic analysis of 16 country case studies. *Health Policy* 2023; **134**: 104860.
- 7 Amimo F, Lambert B, Magit A, Hashizume M. A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa. *Global Health* 2021; **17**(1): 42.
- 8 World Health Organisation. COVID-19 response: Draft resolution proposed by Albania, Australia, Azerbaijan, Bahrain, Bangladesh, Belarus, Bhutan, Bolivia (Plurinational State of), Brazil, Canada, Chile, China, Colombia, Cook Islands, Costa Rica, Djibouti, Dominican Republic, Ecuador, El Salvador, Fiji, Georgia, Guatemala, Guyana, Honduras, Iceland, India, Indonesia, Iraq, Jamaica, Japan, Jordan, Kiribati, Maldives, Marshall Islands, Mexico, Micronesia (Federated States of), Monaco, Montenegro, Morocco, Nauru, Nepal, New Zealand, North Macedonia, Norway, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Qatar, Republic of Korea, Republic of Moldova, Russian Federation, San Marino, Saudi Arabia, Serbia, Singapore, Sri Lanka, Thailand, the African Group and its Member States, the European Union and its Member States, Tonga, Tunisia, Turkey, Ukraine, United Kingdom of Great Britain and Northern Ireland and Uruguay. Seventy-Third World Health Assembly; 2020; Online: *World Health Organisation* 2020.
- 9 United Nations. Resolution 74/274 adopted by the General Assembly on 20 April 2020 International cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19. United Nations General Assembly; 2020; Online: United Nations 2020.
- 10 Turyasingura N, James WG, Vermund SH. COVID-19 vaccine equity in Africa. *Transactions of The Royal* Society of Tropical Medicine and Hygiene 2023; **117**(6): 470-2.
- 11 Mercurio B. TRIPS-plus provisions in FTAs: Recent Trends. In: Bartels L, Ortino F, eds. Regional trade agreements and the WTO legal system. *Oxford University Press* 2006: 215-37.
- 12 World Health Organisation. Immunization Agenda 2030: a global strategy to leave no one behind. *WHO* 2020.
- 13 Grimble R, Wellard K. Stakeholder methodologies in natural resource management: a review of principles, contexts, experiences and opportunities. *Agricultural Systems* 1997; **55(2)**: 173-93.
- United Nations. SDG indicator metadata. Goal 3: Ensure healthy lives and promote wellbeing for all at all ages.
   2023. Available from: <u>https://unstats.un.org/sdgs/metadata/files/Metadata-03-0b-01.pdf</u> (Accessed 25 March 2024)
- 15 United Nations. Progress towards the Sustainable Development Goals: towards a rescue plan for people and planet. Report of the Secretary-General. General Assembly Seventy-eighth session. United Nations General Assembly Economic and Social Council. 2023.
- 16 Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021: **29**; 372: 71. <u>https://doi.org/10.1136/bmj.n71</u>
- 17 Dalglish S, Khalid H, McMahon S. Document analysis in health policy research: the READ approach. *Health Policy and Planning*. 2020; **35**(10): 1424-31.
- 18 Labonté R, Blouin M, Lee K et al. Towards Health-Equitable Globalisation: Rights, Regulation and Redistribution. Final Report to the Commission on Social Determinants of Health. *Globalisation Knowledge Network* 2007.
- 19 Meadows D. Leverage points to intervene in a system. Sustainability Institute, Hartland. 1999.
- 20 World Trade Organization. Trade Therapy: Deepening Cooperation to Stengthen Pandemic Defenses. Conference Edition. WB and WTO. *World Bank Group* 2022.

- 21 Gallogly-Swan K, Thrasher R. Three Pillars of Vaccine Equity: Triaging the Global Vaccination Challenge. Global Economic Governance Initiative Policy Brief 016. *Global Development Policy Center* 2021.
- 22 World Trade Organization. Executive summary: Intellectual Property. In: WHO-WIPO-WTO book. WTO 2023.
- 23 World Trade Organization. An Integrated Health, Trade and IP Approach to Respond to the COVID-19 Pandemic: Second Update, May 2023. Extract from Promoting Access to Medical Technologies and Innovation (Second Edition). WHO-WIPO-WTO. WTO 2023.
- 24 Australian Nursing and Midwifery Federation. Inquiry into Australian Government's Approach to Negotiating Trade and Investment Agreements. Submission to Joint Standing Committee on Trade and Investment Growth. *ANWF* 2023. 4. Available from: <u>https://www.anmf.org.au/media/gvthpyw1/2023-09-22-anmf-submission-inquiry-into-australian-governments-approach-to-negotiating-trade-and-investment-agreements.pdf</u>
- 25 Syam N. A Review of WTO Disputes on TRIPS: Implications for Use of Flexibilities for Public Health. Research Paper 146. *The South Centre* 2022. 36.
- 26 Reji JK and Kumar D. India's Trade in Pharmaceutical Products: A Method for the Classification of Pharmaceutical Products and Recent Trends. Working Paper No.248. *Institute for Studies in Industrial Development* 2022. 22.
- 27 Bhatia R and Kripalani M. Leveraging IBSA for the G20 Troika Presidencies. Paper No.33. *Gateway House* 2023.
- Bown CP. Mega-Regional Trade Agreements and the Future of the WTO. *Global Policy* 2017; **8**(1): 107-12.
- Gaviria M, Kilic B. A network analysis of COVID-19 mRNA vaccine patents. *Nature Biotechnology* 2021; 39(5): 546-8.
- 30 World Trade Organization. Amendment of the TRIPS Agreement. Intellectual Property: TRIPS and Public Health. WTO 2023. Available from: <u>https://www.wto.org/english/tratop\_e/trips\_e/amendment\_e.htm</u> (Accessed 31 Jan 2024)
- 31 Levine D, Sarnoff J. Compelling Trade Secret Transfers. *Hastings Law Journal*, Forthcoming; 2022. Available at SSRN: <u>https://ssrn.com/abstract=4311880</u> (Accessed 15 Feb 2024)
- 32 Davies L. Compulsory licensing: an effective tool for securing access to Covid-19 vaccines for developing states? *Legal Studies* 2023; **43**(1): 86-103. doi:10.1017/lst.2022.24
- 33 Kuhlmann K. Handbook on Provisions and Options for Trade in Times of Crisis and Pandemic. Online: *United Nations Economic and Social Commission for Asia and the Pacific* 2021.
- 34 World Trade Organization. Obligations and Exceptions. Fact Sheet: TRIPS and Pharmaceutical Patents. *WTO*. Available from: <u>https://www.wto.org/english/tratop\_e/trips\_e/factsheet\_pharm02\_e.htm</u> (accessed 1 Feb 2024)
- Adigwe OP, Oturu D. The role of patent waivers and compulsory licensing in facilitating access to COVID-19 vaccines: Findings from a survey among healthcare practitioners in Nigeria. *PLOS Global Public Health* 2022;
   2(7) :e0000683.
- 36 Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Global challenges 2020; **1**(1), 33–46.
- 37 World Bank and World Trade Organization. Trade Therapy: Deepening Cooperation to Strengthen Pandemic Defenses. *World Bank* 2022.
- 38 Daszak P, Amuasi J, das Neves CG, Hayman D, Kuiken T, et al (IPBES Secretariat). IPBES Workshop on Biodiversity and Pandemics: Workshop Report. *Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services (IPBES)* 2020.
- 39 Rourke M, Eccleston-Turner M, Phelan A, Gostin L. Policy opportunities to enhance sharing for pandemic research. *Science* 2020; **368**: 716-718.
- 40 World Health Organization. Medicines Patent Pool (MPP). Available from: <u>https://medicinespatentpool.org/who-we-are/about-us</u> (Accessed 31 Jan 2024)
- 41 World Trade Organization. Doha Declarations. Fourth Ministerial Conference of the WTO, Doha, Quatar. WTO. *wto.org* 2001. Available from: <u>https://www.wto.org/english/res\_e/booksp\_e/ddec\_e.pdf</u> (Accessed 14 April 2024).
- 42 Rees H, Mihigo R, Gray A. Challenges in addressing inequity in access to COVID-19 diagnostics, therapeutics and vaccines in Africa. *South African Journal of Science*. 2022; 118 (5/6)
- 43 Street A and Kelly AH. Tolerable tests: Regulating diagnostic innovation in a global health emergency, lessons from Ebola. *Science, Technology and Human Values.* 2023.
- World Trade Organization. TRIPS Council welcomes MC12 TRIPS waiver decision, discusses possible extension. News. WTO 2022. Available from: <u>https://www.wto.org/english/news\_e/news22\_e/trip\_08jul22\_e.htm</u> (Accessed 25 March 2024).

- 45 Labonté R, Wiktorowicz M, Packer C, Ruckert A, Wilson K, Halabi S. A pandemic treaty, revised international health regulations, or both? *Global Health* 2021; **17**: 128.
- 46 United Nations. Report of the United Nations Secretary-General's High-Level Panel on Access to Medicines. Promoting Innovation and Access to Health Technologies. *United Nations* 2016.
- 47 Georgieva T, Malpass D, Okonjo-Iweala N. A new commitment for vaccine equity and defeating the pandemic. *World Trade Organisation* 2021.
- 48 Medicins Sans Frontieres. 20 countries about to fall off Gavi funding 'cliff', risking their ability to pay for lifesaving vaccines for children long term. Vaccines. MSF Access Campaign. *msfaccess.org* 2017. Available from: <u>https://msfaccess.org/20-countries-about-fall-gavi-funding-cliff-risking-their-ability-pay-life-saving-vaccineschildren</u> (Accessed 14 April 2024)
- 49 Love J. Open letter to the World Health Organization (WHO) and its Member States on the proposal by Costa Rica to create a global pool for rights in the data, knowledge and technologies useful in the prevention, detection and treatment of the coronavirus/Covid-19 pandemic. KEI online: *Knowledge Ecology International* 2020.
- 50 World Health Organization. Proposal for the WHO Pandemic Agreement. A/INB/9/3 Rev.1. Resumed ninth meeting of the intergovernmental negotiating body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response. *WHO* 2024.
- 51 South Centre. South Centre Statement at the 9th session of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response. *WHO* 2024. Available from: <u>https://www.southcentre.int/sc-statement-to-the-who-inb9-march-2024/</u> (Accessed 25 March 2024)
- 52 International Civil Aviation Organization. Guidance Material on Airport Preparedness for Effective Humanitarian Assistance and Disaster Response in Aviation (HADRA). icao.int: *International Civil Aviation Organisation* 2022.
- 53 Bedford J, Farrar J, Ihekweazu C, Kang G, Koopmans M, Nkengasong J. A new twenty-first century science for effective epidemic response. *Nature* 2019; **575**: 130-6.
- 54 Stevens H, Debackere K, Goldman M, Mahoney R, Stevens P, Huys I. Vaccines: Accelerating Innovation and Access: *World Intellectual Property Organisation (WIPO)* 2017.
- 55 Hesselman M, Lane L. Disasters and non-state actors human rights-based approaches. *Disaster Prevention and Management* 2017; **26**: 526-39.
- 56 Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. *Qual Quant* 2018; **52**: 1893-907.
- 57 Stein F. Risky business: COVAX and the financialization of global vaccine equity. *Globalization and Health* 2021; **17**: 1.
- 58 Voysey M, Clemens S, Madhi S et al. (Oxford COVID Vaccine Trial Group). Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials." *Lancet* 2021; **397.10277**: 881–891.
- 59 Dyer O. Covid-19: Drug companies charged South Africa high prices for vaccines, contracts reveal. *BMJ* 2023; **382**: 2112.
- 60 Pauwelyn J, Pelc K. Who Writes the Rulings of the World Trade Organization? A Critical Assessment of the Role of the Secretariat in WTO Dispute Settlement. *Social Science Research Network* 2019.
- 61 Kelsey J. Diversity of Adjudicators in a Reformed ISDS Regime: Is the WTO a good model for developing countries to follow? Investment Treaty News. *International Institute for Sustainable Development* 2020.
- 62 United Nations. Promotion of inclusive and effective international tax cooperation at the United Nations: Nigeria revised draft resolution. Macroeconomic policy questions. Seventy-seventh session of the United Nations General Assembly. *digitallibrary.un.org* 2022.
- 63 Nicolay K, Spix J, Steinbrenner D, Woelfing N. The effectiveness and distributional consequences of excess profit taxes or windfall taxes in light of the Commission's recommendation to Member States. European Parliament policy department for Economic, Scientific and Quality of Life Policies. *EU*. 2023.



